BEAM Down Despite Positive Initial Data From Genetic Disorder Study

Beam Therapeutics Inc. (BEAM) announced positive initial safety and efficacy data from a phase I/II study, which is evaluating its pipeline candidate, BEAM-302, for treating patients with alpha-1 antitrypsin deficiency (AATD).Currently, there are no approved curative treatments for the given indication.Data from the study showed that treatment with a single dose of BEAM-302 demonstrated durable, dose-dependent increases in total and functional alpha-1 antitrypsin (AAT). Also, new production of corrected pro ...